Peptide Research Review: Sports Medicine Study 2026

As peptide supplements continue to gain traction among athletes and active patients seeking faster recovery and enhanced performance, a major new scoping review published in The American Journal of Sports Medicine offers one of the most comprehensive assessments of the current evidence to date. The review, authored by Tewari, Liu, Im, and colleagues (2026), examined peer-reviewed data on six widely discussed peptides — BPC-157, TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu — specifically evaluating their effects on musculoskeletal recovery and performance in both animal and human models. The findings underscore both the promise and the significant limitations of what we currently know.

What This Study Found

The research team conducted a rigorous scoping review following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, searching PubMed with permutations of peptide names combined with musculoskeletal tissue terms including bone, fracture, muscle, tendon, ligament, meniscus, and cartilage. Three independent reviewers screened all identified papers, with a third serving as a tiebreaker in cases of disagreement.

A striking finding was that 67% of identified publications utilized preclinical animal models, most commonly rats. In those animal studies, researchers found that each of the six compounds demonstrated unique mechanisms with promising — but variable — effects on tendon, muscle, bone, and ligament healing. However, the translation of these findings to human clinical benefit remains largely unestablished.

Human clinical studies, by contrast, were described as limited to a handful of investigations, most of which lacked robust controls or rigorous study designs. Where human data did exist, the study suggests it was heterogeneous and revealed only modest improvements at best — primarily in areas of metabolic bone health and degenerative knee pain. The researchers note that significant heterogeneity also existed across studies in terms of dosing protocols and routes of administration, making direct comparisons difficult.

Perhaps most importantly from a safety standpoint, the review identified documented risks associated with certain peptides. MK-677 (also known as ibutamoren), for example, was associated with significant cardiovascular risks including congestive heart failure. The researchers also flagged concerns around metabolic dysfunction, including insulin resistance, as potential adverse effects linked to some compounds in this category.

Based on the totality of the evidence reviewed, the authors concluded that the claimed benefits of emerging peptide supplements for musculoskeletal recovery and performance remain unsubstantiated by current human trials, and that these supplements should not currently be recommended as a replacement or adjunct to existing orthopaedic standard of care.

Clinical Significance

This review carries meaningful clinical weight for several reasons. First, it arrives at a moment when the peptide supplement market is experiencing rapid growth, fueled in large part by marketing claims — many of which, according to the researchers, are not supported by adequate efficacy or safety data. Patients and athletes frequently perceive these compounds as low risk, an assumption this research directly challenges.

For clinicians working in sports medicine, orthopedics, or any field where patients present with musculoskeletal complaints, the study serves as an important reminder that patient-reported use of peptide supplements warrants careful clinical attention. The association of MK-677 with congestive heart failure and the broader risk of metabolic dysfunction suggests that the risk-benefit calculation for these compounds — at least based on current evidence — does not yet favor routine clinical use.

The study also highlights a recurring challenge in evaluating emerging supplements: the gap between promising preclinical findings and validated human outcomes. Animal models, while useful for generating hypotheses and understanding mechanisms, do not reliably predict human responses. Researchers found that while rat models showed encouraging results across multiple peptides and tissue types, this has not yet been replicated with consistency or rigor in human populations.

It is worth noting that the absence of robust evidence is not the same as evidence of absence. The authors do not suggest that further research is without merit. Rather, the review underscores the need for well-designed, placebo-controlled human trials before any of these compounds can be responsibly integrated into clinical protocols.

Current Access and Compliance Context

Understanding the regulatory and access landscape surrounding peptide supplements is essential context for both patients and practitioners. Many of the peptides reviewed — including BPC-157, TB-500, CJC-1295, and ipamorelin — occupy a complex regulatory space. In the United States, several of these compounds have been subject to evolving guidance from the Food and Drug Administration (FDA), and their availability through compounding pharmacies has been a subject of ongoing regulatory scrutiny.

For athletes specifically, compliance with anti-doping regulations is a critical concern. Several peptides in this category — including growth hormone secretagogues such as CJC-1295, MK-677, and ipamorelin — are prohibited by the World Anti-Doping Agency (WADA) and other governing bodies. Athletes subject to drug testing should be aware that use of these compounds may result in sanctions regardless of how they are marketed or obtained.

Practitioners considering patient inquiries about peptide therapies should be familiar with current FDA guidance, applicable compounding regulations, and any sport-specific anti-doping rules relevant to their patient population. When in doubt, consulting with a knowledgeable sports medicine physician or a physician with specific training in peptide therapeutics is advisable.

What Patients Should Know

If you are an athlete or active individual who has encountered marketing for peptide supplements — or who is already using one of the compounds reviewed in this study — there are several important takeaways from this research.

The science is still early. While animal studies suggest interesting mechanisms and potential benefits for tissue healing, human data remains limited, inconsistent, and in many cases methodologically weak. The study suggests that it is premature to draw confident conclusions about efficacy in humans based on what is currently published.

Low risk is not the same as no risk. A common reason patients cite for using peptide supplements is the perception that they are safe. This review directly challenges that assumption, identifying cardiovascular complications and metabolic dysfunction as documented adverse effects associated with at least some compounds in this class.

Dosing and administration vary widely. Because no standardized clinical protocols have been established for these peptides, the doses and delivery methods used across studies — and by consumers — vary considerably. This variability makes it difficult to assess true safety profiles and further underscores the need for professional guidance.

Existing standard of care should not be bypassed. The authors explicitly state that peptide supplements should not currently be recommended as a replacement or adjunct for established orthopaedic treatments. If you are managing a musculoskeletal injury or condition, evidence-based treatments prescribed by a qualified healthcare provider remain the appropriate first line of care.

Open, honest conversations with your physician about any supplements you are taking — or considering — are essential. Many patients do not disclose supplement use to their doctors, which can complicate clinical assessment and create unrecognized risks.

Conclusion

The 2026 scoping review by Tewari, Liu, Im, and colleagues provides an important and timely evidence check on a rapidly growing segment of the supplement market. The study suggests that while peptide compounds like BPC-157, TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu show mechanistic promise in preclinical models, the human evidence required to support their use for musculoskeletal recovery and performance enhancement has not yet been established — and documented risks, including cardiovascular and metabolic complications, cannot be ignored.

At the Peptide Association, our mission is to support evidence-based practice and connect patients with qualified professionals who stay current with the evolving science. If you have questions about peptide therapies and whether they may be appropriate for your health goals, we encourage you to consult with a knowledgeable physician who can provide personalized, medically sound guidance.

Find a qualified peptide-informed physician near you at peptideassociation.org/find-a-doctor.

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice. The content presented here is based on a published scientific review and should not be used as a substitute for professional medical consultation, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you may have regarding a medical condition or the use of any supplement or therapy.

Citation (AMA Format): Tewari K, Liu TP, Im C, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med. 2026;54(8). doi:10.1177/03635465261464420. PMID: 42578445.